CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials

CalciMedica, Inc.

CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.
CRSPA Phase 1/2 in pediatric AIPT completed first cohort; data publication expected Q4 2023.
AKI plan: IND submission H2 2023; Phase 2 trial H1 2024 subject to additional funding.
CARDEA trial showed 56% relative mortality reduction at 30 days (p=0.0165) in severe COVID-19 pneumonia.
Audited recasted financial statements of Private CalciMedica as of Dec 31, 2022 and 2021 filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.